.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Translating Evidence to Clinical Practice: Oral SERDs in HR+/HER2– Metastatic Breast Cancer

On March 8, 2025, a select group of experts in breast cancer (BC) participated in a live workshop to discuss the place of oral selective estrogen receptor degraders (SERDs) in treating hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic BC (MBC). Moderated by Hope S. Rugo, MD, the discussion included the role of oral SERDs as monotherapy or in combination, the optimal integration of SERDs into standard-of-care therapies, and practical approaches including biomarker testing and toxicity management.

EP. 1: Translating Evidence to Clinical Practice: Oral SERDs in HR+/HER2– Metastatic Breast Cancer

April 3rd 2025

On March 8, 2025, a select group of experts in breast cancer (BC) participated in a live workshop to discuss the place of oral selective estrogen receptor degraders (SERDs) in treating hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic BC (MBC). Moderated by Hope S. Rugo, MD, the discussion included the role of oral SERDs as monotherapy or in combination, the optimal integration of SERDs into standard-of-care therapies, and practical approaches including biomarker testing and toxicity management.